

**Remarks:**

**A. Status of the Specification**

The specification has been amended at the suggestion of the Examiner to delete the quotation marks around the objected paragraphs and to identify the amendments made to the paragraph under Table 2 at page 24. Applicants therefore request that the objections to the specification be withdrawn.

**B. Status of the Claims**

Claims 4-26 were pending when the Final Office Action dated June 28, 2005, was mailed to Applicants. Claims 20 and 22 have been amended. Support for the amendments claims can be found throughout the specification and claims as originally filed. Claims 4-26 are therefore currently pending.

**C. Objection of Claims 4-26 Are Overcome**

Claims 4-26 are objected to for various informalities. For instance, claim 6 is objected by the Examiner because a colon was inserted after the term “comprising” but was not underlined. Applicants note that the colon was inadvertently included in claim 6. Because it does not appear that the colon was formally entered into the record, Applicants have not amended claim 6, but rather simply removed the colon. Applicants therefore request that the objection to claim 6 be withdrawn.

With respect to the objections to claims 20 and 22, Applicants note that these claims have been amended at the suggestion of the Examiner. Therefore, Applicants request that the objections be withdrawn.

**D. The Written Description Rejection is Overcome**

Claims 4-20 are rejected under 35 U.S.C. § 112, first paragraph, for failing to comply with the written description requirement. Specifically, the Examiner contends that “[t]here is no original disclosure supporting the recitation that R1 can be 3-N-arylamino...[or] 2-N-arylamino....” Page 2 of the Action.

Applicants disagree. Claims 4-20 prior to any amendments made above satisfy the written description requirement under 35 U.S.C. § 112, first paragraph. However, in an effort to obtain commercially relevant subject matter at this time, Applicants note that independent claim 20 has been amended to recite “...2-N-phenylamino.” Support for this amendment can be found, for example, in Table 1, compound 9, at page 25 of the specification.

Applicants request that the rejection of claims 4-20 under 35 U.S.C. § 112, first paragraph, be withdrawn.

**E. Conclusion**


Applicants believe that the present document is a full and complete response to the Final Office Action dated June 28, 2005. The present case is in condition for allowance, and such favorable action is requested.

**Petition for a Three-Month Extension of Time:**

Pursuant to 37 C.F.R. § 1.136(a), Applicants petition for an extension of time of three months to and including December 28, 2005, in which to respond to the Office Action dated June 28, 2005. Pursuant to 37 C.F.R. § 1.17, a check in the amount of \$510.00 is enclosed, which is the process fee for a three-month extension of time for a small entity status. If the check is inadvertently omitted, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or should an overpayment be included herein, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski Deposit Account No. 50-1212/GOUD:038US.

Should the Examiner have any questions, comments, or suggestions relating to this case, the Examiner is invited to contact the undersigned Applicants' representative at (512) 536-3020.

Respectfully submitted,



Michael R. Krawzsenek  
Reg. No. 51,898  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
512.536.3020 (voice)  
512.536.4598 (fax)

Date: December 15, 2005